Seroconversion and indolent course of COVID-19 in patients with multiple sclerosis treated with fingolimod and teriflunomide

J Neurol Sci. 2020 Sep 15:416:117011. doi: 10.1016/j.jns.2020.117011. Epub 2020 Jul 4.

¹ Department of Basic Medical Sciences, Neuroscience and Sense Organs, University of Bari "Aldo Moro" Policlinico, Italy Piazza Umberto I, Bari, Italy.
² Department of Biomedical Sciences and Human Oncology, Clinic of Infectious Diseases, University of Bari, Bari, Italy.
³ Department of Basic Medical Sciences, Neuroscience and Sense Organs, University of Bari "Aldo Moro" Policlinico, Italy Piazza Umberto I, Bari, Italy. Electronic address: pietro.iaffaldano@uniba.it.

No abstract available

Keywords: Antibodies; COVID-19; Fingolimod; Multiple sclerosis; Seroconversion; Teriflunomide.

Publication types